Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data
Your Lung Cancer Drug May Have Side Effects Not on the Label
This pharmacovigilance study analyzed 27,098 pemetrexed-associated reports in the US FAERS database from 2004 to 2024.
A safety review of over 27,000 reports found that the lung cancer drug pemetrexed may cause side effects not currently listed on its officia…